Skip to content

US · SRZN · BIOTECHNOLOGY

Surrozen, Inc. (SRZN) intrinsic value and stock valuation

$28.46as of 2026-11-21 · Mkt cap 164.13M

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Surrozen, Inc. DCF and intrinsic value

InvestorsCraft values SRZN with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from SRZN’s statements →

Surrozen, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 surrozen.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$3.48M
20192025
Net income
-$-242.03M
20192025
Free cash flow
-$-30.37M
20192025
Total equity
-$-187.76M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$3.48M$10.7M$0.00$12.5M$0.00
Operating income-$-42.09M-$-25.54M-$-45.78M-$-44.34M-$-54.39M
Net income-$-242.03M-$-63.56M-$-43.04M-$-36M-$-52.51M
EPSd-$-32.36M-$-21.69M-$-21.31M-$-15.58M-$-22.44M
Operating cash flow-$-30.24M-$-17.63M-$-40.36M-$-44.15M-$-48.81M
Capital expenditure-$-130K-$-30K-$-400K-$-730K-$-1.27M
Free cash flow-$-30.37M-$-17.65M-$-40.76M-$-44.87M-$-50.08M
Total assets$98.7M$48.5M$46.1M$89.4M$137.2M
Total debt$6.64M$8.47M$3.38M$5.6M$7.79M
Net debt-$-82.61M-$-26.1M-$-32.66M-$-19.09M-$-25.3M
Total equity-$-187.76M-$-21.38M$37.9M$76M$109.7M
Cash and short-term investments$89.3M$34.6M$36M$75.8M$101.9M
Income statement
20252024202320222021
Revenue$3.48M$10.7M$0.00$12.5M$0.00
Cost of revenue$540K$0.00$27.2M$3.27M$3.3M
Gross profit$2.94M$10.7M-$-27.23M$9.23M-$-3.3M
Research and development expenses$29.4M$21.1M$27.2M$37M$36.9M
Selling, general and administrative expenses$16.2M$15.1M$15.8M$19.8M$14.2M
Other expenses-$-540K$0.00-$-24.48M-$-3.27M$0.00
Operating expenses$45M$36.2M$18.6M$53.6M$51.1M
Cost and expenses$45.6M$36.2M$45.8M$56.8M$54.4M
Interest income$3.02M$1.69M$2.34M$780K$70K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$540K$1.44M$1.91M$1.96M$3.3M
Ebitda-$-241.49M-$-62.12M-$-41.13M-$-34.05M-$-51.35M
Operating income-$-42.09M-$-25.54M-$-45.78M-$-44.34M-$-54.39M
Total other income/expenses, net-$-199.93M-$-38.02M$2.74M$8.34M-$-260K
Income before tax-$-242.03M-$-63.56M-$-43.04M-$-36M-$-54.65M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-242.03M-$-63.56M-$-43.04M-$-36M-$-52.51M
Weighted average shares outstanding$7.48M$2.93M$2.02M$2.31M$2.34M
Weighted average diluted shares outstanding$7.48M$2.93M$2.02M$2.31M$2.34M
Balance sheet
20252024202320222021
Cash and short-term investments$89.3M$34.6M$36M$75.8M$101.9M
Net receivables$210K$2.54M$2.15M$1.98M$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$91.6M$38.9M$41.1M$81.3M$105.2M
Property, plant and equipment, net$6.43M$8.36M$3.86M$6.9M$9.38M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$690K$0.00$690K$0.00$21.7M
Total non-current assets$7.17M$9.54M$4.95M$8.13M$32M
Total assets$98.7M$48.5M$46.1M$89.4M$137.2M
Accounts payable$730K$310K$530K$660K$2.72M
Short-term debt$1.29M$1.83M$2.5M$2.23M$2.19M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$9.93M$7.32M$7.15M$9.73M$13.6M
Long-term debt$5.35M$6.64M$880K$3.38M$5.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$276.6M$62.5M$1M$3.7M$13.9M
Capital lease obligations$6.64M$8.47M$3.38M$5.6M$7.79M
Total liabilities$286.5M$69.9M$8.14M$13.4M$27.5M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-527.28M-$-285.26M-$-221.69M-$-178.65M-$-142.65M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$-240K-$-120K
Total equity-$-187.76M-$-21.38M$37.9M$76M$109.7M
Total investments$690K$0.00$690K$51.2M$90.4M
Total debt$6.64M$8.47M$3.38M$5.6M$7.79M
Net debt-$-82.61M-$-26.1M-$-32.66M-$-19.09M-$-25.3M
Cash flow statement
20252024202320222021
Net income-$-242.03M-$-63.56M-$-43.04M-$-36M-$-54.65M
Depreciation and amortization$540K$1.44M$1.91M$1.96M$2.07M
Stock-based compensation$3.83M$4.11M$4.37M$4.52M$2.32M
Change in working capital$3.15M-$-840K-$-3.93M-$-8.42M-$-220K
Accounts receivable$2.33M-$-500K$0.00-$-1.98M$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$140K-$-230K-$-130K-$-2.04M$860K
Net cash provided by operating activities-$-30.24M-$-17.63M-$-40.36M-$-44.15M-$-48.81M
Investments in property, plant and equipment-$-130K-$-30K-$-400K-$-730K-$-1.27M
Acquisitions, net$0.00$0.00$0.00-$-39.04M$0.00
Net cash used for investing activities-$-130K-$-30K$51.7M$38.3M-$-77.71M
Common stock issued$85.1M$16M$280K$40K$124.2M
Common stock repurchased$0.00$0.00-$0.00-$-2.61M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$85.1M$16.2M$280K-$-2.56M$124.6M
Net change in cash$54.7M-$-1.48M$11.6M-$-8.4M-$-1.89M
Cash at end of period$89.9M$35.3M$36.7M$25.1M$33.5M
Operating cash flow-$-30.24M-$-17.63M-$-40.36M-$-44.15M-$-48.81M
Capital expenditure-$-130K-$-30K-$-400K-$-730K-$-1.27M
Free cash flow-$-30.37M-$-17.65M-$-40.76M-$-44.87M-$-50.08M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Surrozen, Inc.

        Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

        CEO
        Craig Parker
        Employees
        44
        Beta
        0.51

        Explore

        Frequently asked questions

        What is the intrinsic value of Surrozen, Inc. (SRZN)?

        Surrozen, Inc. (SRZN) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SRZN undervalued?

        SRZN trades at a price of $28.46 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.